{
  "pmcid": "7079046",
  "abstract": "300-word version:\n\nTitle: Randomised Controlled Trial of CEA-Specific Fluorescence Imaging in Cytoreductive Surgery for Colorectal Cancer\n\nBackground: This multicentre pilot study aimed to assess the role of carcinoembryonic antigen (CEA)-specific fluorescence imaging using SGM-101 during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) in patients with peritoneal metastasized colorectal cancer.\n\nMethods: Fourteen patients diagnosed with peritoneal metastases of colorectal origin were included. SGM-101 was administered intravenously 4â€“6 days before surgery. The primary outcome was the change in the peritoneal carcinomatosis index (PCI) due to fluorescence imaging, measured intraoperatively. Randomisation and blinding details were not applicable as this was a pilot study.\n\nResults: A correct change in PCI due to fluorescence imaging was observed in 4 of the 14 patients. The median clinical PCI was 7, and the median fluorescence-based PCI (fPCI) was 6.5. SGM-101 was well tolerated, with no allergic or anaphylactic reactions reported. The sensitivity and specificity of fluorescence imaging were 98.5% and 62.2%, respectively, with an accuracy of 85.4%. Of the 103 lesions excised, 65 of the 66 malignant lesions were fluorescent, resulting in a positive predictive value of 82.3% and a negative predictive value of 95.8%.\n\nInterpretation: The use of SGM-101 in patients with peritoneally metastasized colorectal carcinoma is feasible and allows for intraoperative detection of tumor deposits, potentially altering the PCI and improving surgical outcomes. The technique demonstrated high sensitivity and accuracy, indicating its potential benefit in achieving more complete cytoreduction. No trial registration or funding details were provided.",
  "word_count": 242
}